TipRanks
Fate Therapeutics (FATE)
NASDAQ:FATE
US Market
FATE
Fate Therapeutics
RESEARCH TOOLSreports
Want to see FATE full AI Analyst Report?

Fate Therapeutics (FATE) Stock News & Sentiment

1,293 Followers
Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
Premium
Class Action
Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
4d ago
FATE
Fate Therapeutics Secures CIRM Grant for FT819 Lupus Trial
Premium
Company Announcements
Fate Therapeutics Secures CIRM Grant for FT819 Lupus Trial
8d ago
8K
FATE
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
Premium
Company Announcements
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
1M ago
FATE
Fate Therapeutics Advances FT819 Cell Therapy Into Phase 2 Lupus Nephritis Trial
Premium
Company Announcements
Fate Therapeutics Advances FT819 Cell Therapy Into Phase 2 Lupus Nephritis Trial
1M ago
FATE
Analyst Maintains Hold on Fate Therapeutics as Off‑the‑Shelf CAR‑T Pipeline Advances but Key Efficacy Data Remain Early
Premium
Ratings
Analyst Maintains Hold on Fate Therapeutics as Off‑the‑Shelf CAR‑T Pipeline Advances but Key Efficacy Data Remain Early
2M ago
FATE
FATE Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
FATE Upcoming Earnings Report: What to Expect?
2M ago
FATE
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
Premium
Ratings
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
3M ago
FATE
More FATE News >

FATE News on the Web

Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
TipRanks News
Neutral
Top Fate Therapeutics Executives Quietly Cash Out in Major Insider Stock Move
TipRanks News
Neutral
BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc
GuruFocus News
Neutral
Fate Therapeutics (FATE) Gets a Hold from Needham
TipRanks News
Neutral
Fate Gets FDA IND Clearance For FT839 To Initiate Phase 1/2 Trial In Autoimmune Diseases
rttnews
Bullish
Fate Therapeutics (FATE) Receives FDA Clearance for CAR-T Therapy FT839
GuruFocus News
Bullish
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
TipRanks News
Bullish
Fate Therapeutics announces FDA clearance of FT839 IND application
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
FATE
Sector Average
Media Buzz
This Week2 articles
Weekly Average1.5 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is FATE’s Media Buzz Sentiment?
2 articles about FATE were published this week. In an average week, 1.5 articles are published.
    What is FATE’s weekly average amount of articles?
    In an average week, 1.5 articles about FATE are published.
      What is FATE’s News Sentiment?
      50% of articles about FATE were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        XERSXeris Pharmaceuticals
        QTTBQ32 Bio
        ABTAbbott Laboratories
        GMABGenmab
        BAYRYBayer
        Showing the stocks with the most bullish news sentiment over the past week